Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ERIC 2018 | Cellular therapies in CLL: from transplant to CAR T-cells?

Jennifer Brown • 25 Oct 2018
ERIC 2018
Chronic Lymphocytic Leukemia Leukemia CAR-T Ibrutinib

Jennifer Brown, MD, PhD, of the Dana-Farber Cancer Institute, Boston, MA, discusses cellular therapies in chronic lymphocytic leukemia (CLL), starting with transplant and now moving towards CAR T-cells. Excitingly, treatment with ibrutinib has been shown to improve response rates to CAR T-cells in CLL; however, the track record of this novel therapy is of course shorter than that of stem cell transplantation. This interview was recorded at the European Research Initiative on CLL (ERIC) International Meeting 2018, held in Barcelona, Spain.

More from Jennifer Brown

1:18
Investigating acquired mutations in patients with R/R CLL who progressed in the ALPINE study
Jennifer Brown • 11 Dec 2023
1:55
Genomic evolution of patients with CLL who progress on pirtobrutinib in the BRUIN trial
Jennifer Brown • 11 Dec 2023
1:43
Extended follow-up of the ALPINE trial: superior outcomes with zanubrutinib in R/R CLL/SLL
Jennifer Brown • 11 Dec 2023
1:24
Sequencing of BTK inhibitors in CLL
Jennifer Brown • 6 Sep 2023

Related Videos

1:40
The role of CPX-351 in the AML treatment landscape & insights into the AMLSG 30-18 trial
Felicitas Thol • 19 Apr 2024
3:21
Integrating genomics and MRD in transplant decision-making for patients with AML
Jurjen Versluis • 22 Apr 2024
4:19
Blinatumomab to achieve remission and consolidation with haploSCT for pediatric ALL
Alberto Olaya-Vargas • 15 Apr 2024
3:32
Improving CAR-T therapy for ALL & lymphoma: allogeneic products & reducing CRS/ICANS
Sridhar Chaganti • 16 Apr 2024
The content of VJHemOnc is intended for healthcare professionals